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Background: Cross resistance between androgen-receptor targeting therapies
(ARTs) (abiraterone acetate plus prednisone [ABI + P] or enzalutamide [ENZ]) for
treatment of metastatic castration-resistant prostate cancer (mCRPC) may affect
responses to second ART (ART2).
Objective: To establish treatment duration and prostate-specific antigen (PSA)
response of ART2 in real-world mCRPC patients treated with or without other
life-prolonging drugs (LPDs; ie, docetaxel, cabazitaxel, or radium-223) between
ART1 and ART2.
Design, setting, and participants: Castration-resistant prostate cancer patients,
diagnosed between 2010 and 2016 were retrospectively registered in Castra-
tion-resistant Prostate Cancer Registry (CAPRI). Patients treated with both ARTs
were clustered into two subgroups: ART1 > ART2 or ART1 > LPD > ART2.. P.O. Box 1738, 3000 DR Rotterdam, The Netherlands. Tel.: +31 10 408 8696.
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Outcome measurements and statistical analysis: Outcomes were 50% PSA re-
sponse and treatment duration of ART2. Descriptive statistics and binary logistic
regression after multiple imputations were performed.
Results and limitations: A total of 273 patients were included with a median
follow-up of 8.4 mo from ART2. Patients with ART1 > ART2 were older and had
favourable prognostic characteristics at ART2 baseline compared with patients with
ART1 > LPD > ART2. No differences between ART1 > ART2 and ART1 > LPD > ART2
were found in PSA response and treatment duration. Multivariate analysis sug-
gested that PSA response of ART2 was less likely in patients with visceral metastases
(odds ratio [OR] 0.143, p = 0.04) and more likely in patients with a relatively longer
duration of androgen-deprivation treatment (OR 1.028, p = 0.01) and with ABI + P
before ENZ (OR 3.192, p = 0.02). A major limitation of this study was missing data, a
common problem in retrospective observational research.
Conclusions: The effect of ART2 seems to be low, with a low PSA response rate and a
short treatment duration irrespective of interposed chemotherapy or radium-223,
especially in patients with short time on castration, visceral disease, and ENZ before
ABI + P.
Patient summary: We observed no differences in outcomes of patients treated with
sequential abiraterone acetate plus prednisone (ABI + P) and enzalutamide (ENZ)
with or without interposed chemotherapy or radium-223. In general, outcomes
were lower than those in randomised trials, questioning the additional effect of
second treatment with ABI + P or ENZ in daily practice.
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Annually, 3000 patients develop metastatic castration-
resistant prostate cancer (mCRPC) in the Netherlands
[1]. Multiple treatment options are available, including
taxane (TAX) chemotherapy (docetaxel [DOC] and cabazi-
taxel [CAB]), androgen-receptor targeting therapies (ARTs;
abiraterone acetate plus prednisone [ABI + P] and enzalu-
tamide [ENZ]), and an alpha-emitting radioisotope (radium-
223 [Ra-223]). One of the challenges is selecting the most
optimal treatment sequence.
Sequencing of ARTs is of particular interest, since the two
ARTs used target the androgen signalling pathway. Acquired
resistance to ABI + P and ENZ is inevitable. Molecular
mechanisms of resistance to both ARTs are similar and
cross resistance is a common phenomenon [2]. Clinical
findings from one prospective and several retrospective
studies support this hypothesis, showing low prostate-
specific antigen (PSA) responses of second ART (ART2),
especially in patients treated with ENZ before ABI + P [3–
6]. A short interval between both ARTs and progression on
ART1 are related to low PSA responses [7,8].
The European Association of Urology advises the use of
DOC after first-line ART because of concerns about cross
resistance [9], but no solid evidence points to resensitisa-
tion following the “sandwich” use of TAX prior to ART2. One
small retrospective study recently reported similar PSA
responses (21–30%) in patients treated with both ARTs
directly after each other or with TAX in between [10].
However, available data on the activity of ART2 are not
easily translated into daily clinical practice, since data are
based on small study populations (<150 patients) with
highly selected patients either participating in early access
programmes or treated in academic institutions, or onPlease cite this article in press as: Kuppen MCP, et al. Real-world O
with or Without Interposed Life-prolonging Drugs in Metastatic 
Castration-resistant Prostate Cancer Registry. Eur Urol Oncol (20follow-up of patients who participated in randomised
controlled trial.
The aim of this study is to investigate PSA response and
treatment duration of ART2 depending on treatment
sequence in a real-world setting. We provide outcomes
on sequential ARTs or ARTs with interposed life-prolonging
drugs (LPDs) such as TAX or Ra-223.
2. Patients and methods
2.1. Study design and setting
Castration-resistant Prostate Cancer Registry (CAPRI) is an
investigator-initiated, observational, multicentre cohort
study in 20 Dutch hospitals. Data collection started after
approval by the local medical ethics committee and hospital
board. The study design has been described before
[11]. Castration-resistant prostate cancer patients were
included retrospectively from 1 January 2010 until 31 De-
cember 2015, with regular updates of all data until
31 December 2017. All treatment decisions as well as the
use of diagnostics, response measurements, and supportive
care were made by treating physicians and were not
protocol amended. CAPRI is registered in the Dutch Trial
Registry as NTR3591.
2.2. Participants
Patients having mCRPC who were treated with both ABI + P
and ENZ before 1 July 2017 with one line of TAX or Ra-223
between both ARTs were included in this analysis. Patients
treated with DOC for metastatic hormone-sensitive pros-
tate cancer were excluded.utcomes of Sequential Androgen-receptor Targeting Therapies
Castration-resistant Prostate Cancer: Results from the Dutch
19), https://doi.org/10.1016/j.euo.2019.09.005
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(1) ABI + P directly followed by ENZ or vice versa (ART1 >
ART2) and (2) ABI + P followed by ENZ or vice versa interposed
with TAX or Ra-223 treatment (ART1 > LPD > ART2).
Additional subgroup analyses were performed based on
the following parameters:
1 Sequence of ABI + P and ENZ: ABI + P before ENZ (ABI
+ P > ENZ) or ENZ before ABI + P (ENZ > ABI + P)
2 ART1 treatment duration: “long ART1 treatment” (ie,
ART1 treatment duration 12 wk according to the
Prostate Cancer Clinical Trials Working Group 3 [PCWG
3] criteria [12]) or “short ART1 treatment” (ie, ART1
treatment duration <12 wk)
3 Interval between ART1 and ART2: interval between ART1
and ART2 calculated as the time between stop of ART1
and start of ART2, with a cut-off of 40 d based on previous
published work [7]
2.3. Study size
In all, 273 participants were included from a total of
3616 mCRPC patients.
2.4. Follow-up and data collection
Predefined and readily available data from medical records
were retrospectively collected by trained data managers.Fig. 1 – Flowchart of treatment sequencing in patients treated with both ARTs.
ART1 = first AR-targeting therapy; ART2 = second AR-targeting therapy; CAB = ca
drug; mCRPC = metastatic castration-resistant prostate cancer; Ra-223 = radium
Please cite this article in press as: Kuppen MCP, et al. Real-world O
with or Without Interposed Life-prolonging Drugs in Metastatic 
Castration-resistant Prostate Cancer Registry. Eur Urol Oncol (20Baseline characteristics (including performance score, symp-
toms, extent of disease, and laboratory values) were included in
the analysis if they were documented from 6 wk before to 1 wk
after the start of ART2. All patients were followed until death,
loss to follow-up, or 31 December 2017. Follow-up durationwas
calculated from the start date of ART2 to the last recorded date.
2.5. Outcome
The primary outcome was PSA response. PSA response was
defined as the maximum change from baseline PSA levels
(in percentages) without confirmation of second measure.
In case no decline was present, responses were measured at
12 wk (according to the PCWG 3 criteria for response
measurement [12]) or, if treatment was for <12 wk, at the
end of treatment or start of next treatment. PSA response
was defined as a 50% PSA decline from baseline [12].
The secondary outcome was treatment duration, and
was calculated as the interval between the start and stop of
ART2. If the stop date was unknown, treatment duration
was specified as the time (1) from the start of ART2 to the
start of next treatment or (2) from the start of ART2 to death
if ART2 was the last treatment. Patients still alive at the end
of follow-up and without a new line of therapy were
censored at the date of last known visit.
2.6. Statistical analysis
The sample size was not based on power calculations.
Descriptive statistics were performed. To test the ABI + P = abiraterone acetate plus prednisone; AR = androgen receptor;
bazitaxel; DOC = docetaxel; ENZ = enzalutamide; LPD = life-prolonging
-223.
utcomes of Sequential Androgen-receptor Targeting Therapies
Castration-resistant Prostate Cancer: Results from the Dutch
19), https://doi.org/10.1016/j.euo.2019.09.005
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Whitney U test, and t test were used. Waterfall plots
indicate PSA response per subgroup. Missing baseline
characteristics were imputed using multiple imputations
with Monte Carlo Markov Chain method. Binary logistic
regression to assess the effect of baseline variables on PSA
response was performed. A p value of <0.05 was considered
statistically significant. IBM SPSS Statistics version 24.0
(IBM, Armonk, NY, USA) was used for all analyses.
3. Results
In total, 273 patients (8%) were treated with both ABI + P and
ENZ before 1 July 2017. Of these patients, 148 were treated
with ART1 > ART2 and 125 with ART1 > LPD > ART2, includ-
ing 61 patients (48%) treated with DOC, 41 (33%) with CAB,
and 23 (19%) with Ra-223 between ART1 and ART2 (Fig. 1).
In ART1 > ART, 86 patients (58%) received ABI + P > ENZ
and 62 (44%) received ENZ > ABI + P compared with
86 patients (69%) with ABI + P > ENZ and 39 (31%) with
ENZ > ABI + P in ART1 > LPD > ART2 (Fig. 1).
Median follow-up from ART2 was 8.4 mo (range 0.3–35.8
mo). At the end of the study, 202 all-cause deaths (74%) have
occurred, 38 patients (14%) were lost to follow-up, and 33
(12%) were still in follow-up (median follow-up from ART2
of 11.1 mo).
3.1. Baseline characteristics
Patients in the ART1 > ART2 sequence were older at the
start of ART2 than patients in ART1 > LPD > ART2 (75 vsFig. 2 – Waterfall plot of PSA response during second AR-targeting therapy (AR
dotted line indicates the threshold of 50% PSA decline. AR = androgen recepto
(docetaxel, cabazitaxel, or radium-223); PSA = prostate-specific antigen.
Please cite this article in press as: Kuppen MCP, et al. Real-world O
with or Without Interposed Life-prolonging Drugs in Metastatic 
Castration-resistant Prostate Cancer Registry. Eur Urol Oncol (2073 yr, p < 0.01; Table 1). ART1 > ART2 patients had favour-
able prognostic characteristics: less visceral metastases
(12% vs 22%, p = 0.04), higher haemoglobin levels (7.5 vs
6.9 mmol/l, p < 0.01), lower lactate dehydrogenase (LDH)
levels (240 vs 270 U/l, p = 0.02), and lower PSA levels (114 vs
170 mg/l, p = 0.03).
In ART1 > ART2, more patients had short ART1 treat-
ment (<12 wk) than those in ART1 > LPD > ART2 (24% vs
11%, p < 0.01), but no differences in PSA response of ART1
were observed. In the ART1 > LPD > ART2 sequence, 24% of
patients had a 50% PSA decline on interposed LPDs (28% on
TAX and 9% on Ra-223; Table 1).
3.2. PSA response of ART2
PSA response of ART2 was similar in ART1 > ART2 to that in
ART1 > LPD > ART2 (20% vs 18%, p = 0.297; Table 2 and
Fig. 2). PSA response of ART2 in ART1 > ART2 was similar to
PSA response of LPD in ART1 > LPD > ART2 (20% vs 24%,
p = 0.80). PSA response of ART2 was lower in patients with
ART1 treatment 12 wk than in patients with ART1
treatment <12 wk, but this did not reach statistical
significance (18% vs 26%, p = 0.08). No differences in PSA
response were found based on ABI + P and ENZ sequence,
and interval between ART1 and ART2 (Table 3).
3.3. Treatment duration
At the end of follow-up, 9% of ART1 > ART2 patients were
still on treatment compared with 3% of ART1 > LPD > ART2
patients. Fig. 3 shows median treatment duration of ART2:T2). Maximum percentage change from baseline PSA per patient. The
r; ART1 = first AR-targeting therapy; LPD = other life-prolonging drug
utcomes of Sequential Androgen-receptor Targeting Therapies
Castration-resistant Prostate Cancer: Results from the Dutch
19), https://doi.org/10.1016/j.euo.2019.09.005
Table 1 – Baseline characteristics at the start of second AR-targeting therapy.
N = 273 ART1 > ART2
N = 148
ART1 > LPD > ART2
N = 125
p value
Age (yr) Median (range) 75 (53–80) 73 (50–90) 0.002 **
75 yr (%) 54 38 0.010 *









Opioid use (%) Yes 16 23 0.968
No 22 33
Missing 62 44
Disease state (%) N0/N1/Nx 14/41/45 20/38/42 0.260
M0/M1/Mx (bone) 5/80/15 3/82/14 0.554
M0/M1/Mx (visceral) 44/12/45 34/22/44 0.016 *
Gleason score (%) 7 34 37 0.715
8–10 53 53
No histology 1 2
Metastasis biopsy 1 1
Missing 10 7
Time castration to mCRPC (mo) Median (IQR) 14.3 (8–27) 13.4 (9–22) 0.725
Missing (%) 0 0
Hb (mmol/l) Median (IQR) 7.5 (6.8–8.2) 6.9 (6.0–7.8) <0.001 **
Missing (%) 10 7
ALP (U/l) Median (IQR) 129 (88–224) 144 (86–258) 0.581
Missing (%) 11 10
LDH (U/l) Median (IQR) 240 (190–283) 270 (204–364) 0.017 *
Missing (%) 30 22
PSA (mg/l) Median (IQR) 114 (32–391) 170 (85–444) 0.033 *
Missing (%) 8 7




ART1 treatment (%) ENZ 42 31 0.068
ABI + P 58 69
Treatment duration of ART1 (mo) Median (IQR) 7.1 (3.1–13.6) 7.4 (5.2–12.3) 0.869
12 wk (%) 24 11 0.005 **
PSA response to ART1 (%) 50% PSA decline 51 54 0.442
<50% PSA decline 35 30
PSA response missing 14 16
Time between discontinuation
of ART1 and start of ART2 (mo)
Median (IQR), <1 (0–2), 27 7 (5–10), 33 <0.001 **
missing (%)a 53 0
<40 d (%) 20 67
40 d (%)
Interposed LPD b (%) Docetaxel NA 49
Cabazitaxel 33
Radium-223 18
Treatment duration of interposed LPD b (cycles) Median (range) NA 6 (1–15)
6 cycles (valid %) 68
10 cycles (valid %) 16
Missing (%) 5
PSA response to interposed LPD b (%) 50% PSA decline NA 24
<50% PSA decline 49
PSA response missing 27
ABI + P = abiraterone acetate plus prednisone; ALP = alkaline phosphatase; AR = androgen receptor; ART1 = first AR-targeting therapy; ART2 = second AR-
targeting therapy; ECOG PS = Eastern Cooperative Oncology Group performance score; ENZ = enzalutamide; Hb = haemoglobin; IQR = interquartile range; LDH
= lactate dehydrogenase; LPD = life-prolonging drug; mCRPC = metastatic castration-resistant prostate cancer; NA = not available; PSA = prostate specific
antigen.
a Patients with missing ART1 stop date.
b Characteristics of interposed life-prolonging treatment in ART1 > LPD > ART2.
* Significant at p < 0.05.
** Significant at p < 0.01.
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Table 2 – PSA response and treatment duration of second AR-targeting therapy.
N = 273 ART1 > ART2
N = 148
ART1 > LPD > ART2
N = 125
p value
PSA response Median change from baseline a (IQR) –21% (–56% to +46%) –18% (–50% to +73%) 0.315
50% PSA decline (%)
<50% PSA decline (%) 20 18 0.297
Missing (%) 45 57
35 25
Treatment duration of ART2 Median (IQR), censored (%) b 3.2 (1.9–7.5), 9 3.2 (1.8–5.9), 3 0.042 *
3 mo (valid %) 52 49
>3 mo (valid %) 48 51 0.621
PSA response on line after ART1 c 50% PSA decline (%) 20 24 0.801
<50% PSA decline (%) 45 49
Missing (%) 35 27
AR = androgen receptor; ART1 = first AR-targeting therapy; ART2 = second AR-targeting therapy; IQR = interquartile range; LPD = life-prolonging drug; PSA
= prostate-specific antigen.
a Measured as relative change from baseline value (negative values indicate a PSA decline, positive values a PSA increase).
b Still on treatment at the end of follow-up.
c PSA response rate of ART2 in ART1 > ART2 and of interposed LPD in ART1 > LPD > ART2.
* Significant at p < 0.05.
Table 3 – PSA response and treatment duration of second AR-targeting therapy based on different subgroups.
ABI + P and ENZ sequence ART1 treatment duration Interval between ART1 and ART2
ENZ > ABI + P
N = 101
ABI + P > ENZ
N = 172









PSA response 50% PSA decline (%) 14 23 0.159 18 26 0.078 20 19 0.461
<50% PSA decline (%) 51 50 53 38 45 54
Missing (%) 36 27 29 36 35 27
Treatment
duration (mo)
Median (IQR) 3.2 (1.8–7.3) 3.2 (1.9–5.9) 0.158 3.2 (1.9–6.7) 3.2 (1.8–5.8) 0.573 3.2 (1.9–6.4) 3.2 (1.8–6.5) 0.364
Censored (%) a 12 3 6 6 8 5
3 mo (valid %) 55 48 0.276 51 49 0.825 53 48 0.437
>3 mo (valid %) 45 52 49 51 47 52
ABI + P = abiraterone acetate plus prednisone; AR = androgen receptor; ART1 = first AR-targeting therapy; ART2 = second AR-targeting therapy;
ENZ = enzalutamide; IQR = interquartile range; PSA = prostate-specific antigen.
a Still on treatment at the end of follow-up.
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ART2 and 3.2 mo (IQR 1.8–5.9 mo) in ART1 > LPD > ART2
(p = 0.04). Patients with ART1 > ART2 had higher probabili-
ty of longer treatment duration (hazard ratio 0.773, 95%
confidence interval 0.603–0.993, p = 0.04). Patients with a
response to ART2 had a median treatment duration of
7.3 mo (IQR 4.1–13.0 mo).
No differences were observed in ART2 treatment duration
between ABI + P and ENZ sequence, ART1 treatment dura-
tion, and interval between ART1 and ART2 (Table 3).
3.4. Multivariate analyses
Eighty-three patients (30%) were excluded from multivari-
ate binary logistic regression due to missing PSA response of
ART2 (Table 4). There was no difference in PSA response of
ART2 between ART1 > ART2 and ART1 > LPD > ART2 (odds
ratio [OR] 0.890, p = 0.89). Visceral metastases were
associated with lower PSA response rates (OR 0.143,
p = 0.04), while longer time on androgen-deprivation
therapy (OR 1.028, p = 0.01) and ABI + P before ENZ (ORPlease cite this article in press as: Kuppen MCP, et al. Real-world O
with or Without Interposed Life-prolonging Drugs in Metastatic 
Castration-resistant Prostate Cancer Registry. Eur Urol Oncol (203.192, p = 0.02) were associated with higher PSA response
rates (Table 4).
After the exclusion of 32 patients treated with ART1 for
<12 wk from multivariate analysis, time on androgen-
deprivation therapy remained the only significant factor for
PSA response (OR 1.034, p = 0.02).
4. Discussion
In this retrospective analysis of real-world data, we
reported outcomes of sequential treatment with both ARTs
with or without interposed TAX or Ra-223. To our
knowledge, this is the largest multicentre population in
which patients are treated according to the views and
opinions of their medical oncologists and urologists.
Outcomes therefore reflect current daily practice.
Patients with ART1 > ART2 had better prognostic factors
at the start of ART2 (less visceral disease, higher haemo-
globin, lower LDH, and lower PSA) than ART1 > LPD > ART2
patients. One could speculate that physicians decided to
administer TAX or Ra-223 rather than the other ART inutcomes of Sequential Androgen-receptor Targeting Therapies
Castration-resistant Prostate Cancer: Results from the Dutch
19), https://doi.org/10.1016/j.euo.2019.09.005
Fig. 3 – Treatment duration (in months) during second AR-targeting therapy (ART2). AR = androgen receptor; ART1 = first AR-targeting therapy;
LPD = other life-prolonging drug (docetaxel, cabazitaxel, or radium-223).
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seemingly have little faith in a meaningful response to ART2
in patients with progression on ART1. This seems unjustified
based on similar response rates to ART2 in ART1 > ART2
(20%) to that on LPDs in ART1 > LPD > ART2 (24%).
We observed a PSA response of ART2 in 20% of patients
with or without interposed TAX or Ra-223, and a median
treatment duration of 3 mo. PSA response is in line with
previously published reports on ART2 (4–30% [4–6,13–16]),
but low compared with phase III randomised controlled
trials for ABI + P and ENZ (62–78% in chemotherapy-naïve
and 38–54% in postchemotherapy treatment [17–20]). Low
PSA responses and short treatment duration can be a result
of cross-resistance between ABI + P and ENZ. Mechanisms
of resistance are complex and not completely understood,
but it is proposed that they include both androgen receptor
(AR)-dependent mechanisms (eg, AR aberrations, including
amplification, genomic structural variants, or splice variants
such as AR-V7) and AR-independent mechanisms (eg,
neuroendocrine transformation or glucocorticoid receptor
overexpression) [2]. Since mechanisms of resistance are
overlapping between ABI + P and ENZ, cross resistance may
lead to low efficacy of ART2.
However, a low PSA response rate and a short treatment
duration of ART2 can also be the result of the advanced
disease state. Most patients were treated with ART2 in line 3
(47%) or line 4 (30%). An Italian multicentre study showed
that the biochemical response rates decreased to 38%, 24%,
and 16%, respectively, on second, third, and fourth lines
irrespective of the treatment sequence [21].
Presence of visceral disease and shorter time between
the start of androgen-deprivation therapy and mCRPC were
predictive of a poor PSA response of ART2. Visceral disease
and rapid time to castration resistance are knownPlease cite this article in press as: Kuppen MCP, et al. Real-world O
with or Without Interposed Life-prolonging Drugs in Metastatic 
Castration-resistant Prostate Cancer Registry. Eur Urol Oncol (20prognostic factors for overall survival [22,23], but can
possibly impact PSA response due to a correlation between
survival and PSA response rate [24,25].
We hypothesised that patients who discontinued ART1
due to other reasons than progression would have better
effect of ART2, since resistance (either primary or acquired)
to ART1 has not occurred. Since the exact reason of
discontinuation was not easily evaluable due to missing
values and the absence of strict progression criteria,
treatment duration was used as a proxy for the reason of
discontinuation. Toxicity mainly occurs in the initial
months, making a duration of <12 wk an indicator of
toxicity. These patients tended to have higher PSA response
rates than patients with ART1 treatment 12 wk (26% vs
18%), but this difference was not clinically relevant.
Treatment sequence of ABI + P and ENZ has also been
argued to affect the response of ART2 with favourable
effects for ABI + P > ENZ than for ENZ > ABI + P [4–
7,13,26,27]. In our study, patients with ABI + P > ENZ also
had better PSA response rates of ART2 (OR 3.192, p = 0.02)
without differences in treatment duration. The beneficial
effect of ABI + P > ENZ on PSA response did not hold after
exclusion of patients with ART1 treatment <12 wk (OR
2.060, p = 0.19).
We used PSA kinetics and treatment duration as
indicators for treatment efficacy of ART2, but the effect
on overall survival and progression-free survival could not
be estimated. Post hoc analyses of phase III trials of ABI + P
and ENZ demonstrated a strong correlation between PSA
kinetics during ABI + P and ENZ and overall survival [24,25].
Although the PSA response rate of ART2 is fairly low and
median treatment duration is short, patients who had a PSA
response of ART2 had a clinically relevant duration of ART2
treatment (7.3 mo). ART2 may therefore offer a benefit in autcomes of Sequential Androgen-receptor Targeting Therapies
Castration-resistant Prostate Cancer: Results from the Dutch
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Table 4 – Univariate and multivariate binary logistic regression for PSA response.
Univariate analysis of original data Multivariate analysis of pooled data after
imputation (N = 190)
N OR 95% CI p value OR 95% CI p value
Age (yr), cont. 190 1.027 0.986–1.069 0.199 1.013 0.959–1.070 0.643
Charlson score
6 127 REF – – REF – –
7–8 52 0.613 0.345–1.545 0.266 0.582 0.216–1.565 0.283
>9 11 0.815 0.384–5.033 0.684 1.162 0.206–6.563 0.865
ECOG PS
0 36 REF – – REF – –
1 81 0.707 0.259–1.452 0.412 0.396 0.140–1.120 0.081
2 38 0.895 0.304–2.184 0.814 0.495 0.125–1.963 0.316
Opioid use
No 54 REF – – REF – –
Yes 40 1.196 0.470–3.042 0.707 1.312 0.463–3.719 0.609
Disease state
N1 vs N0 107 0.629 0.265–1.494 0.293 0.696 0.221–2.192 0.532
M1 vs M0 (bone) 162 1.239 0.241–6.369 0.798 5.414 0.702–41.770 0.104
M1 vs M0 (visceral) 91 0.340 0.104–1.111 0.074 0.143 0.023–0.879 0.037
Gleason score (%)
7 65 REF – – REF – –
8–10 104 0.578 0.293–1.139 0.113 0.692 0.287–1.668 0.411
Time castration to mCRPC (mo), cont. 190 1.020 1.004–1.036 0.013 * 1.028 1.006–1.050 0.013 *
Hb (mmol/l), cont. 183 0.979 0.727–1.317 0.888 0.706 0.424–1.177 0.180
ALP (U/l), cont. 183 1.000 0.999–1.002 0.720 1.000 0.998–1.002 0.760
LDH (U/l), cont. 151 1.000 0.998–1.001 0.500 1.000 0.998–1.002 0.725
PSA (mg/l), cont. 190 1.000 1.000–1.0001 0.931 1.000 0.999–1.000 0.535
Docetaxel prior to ART1
No 75 REF – – REF – –
Yes 115 0.717 0.377–1.362 0.309 0.667 0.292–1.525 0.337
Treatment sequence
ENZ > ABI + P 65 REF – – REF – –
ABI + P > ENZ 125 1.652 0.819–3.334 0.161 3.192 1.195–8.529 0.021 *
Treatment sequence
ART1 > ART2 95 REF – – – – –
ART1 > LPD > ART2 94 0.713 0.376–1.349 0.298 0.890 0.359–2.206 0.890
Treatment duration of ART1 (wk)
>12 158 REF – – REF – –
12 32 2.018 0.915–4.453 0.082 3.293 0.978–11.094 0.054
50% PSA decline on ART1
No 56 REF – – REF – –
Yes 109 0.914 0.442–1.888 0.807 1.125 0.395–3.207 0.824
ABI + P = abiraterone acetate plus prednisone; ALP = alkaline phosphatase; AR = androgen receptor; ART1 = first AR-targeting therapy; ART2 = second AR-
targeting therapy; CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance score; ENZ = enzalutamide; Hb = haemoglobin;
IQR = interquartile range; LDH = lactate dehydrogenase; LPD = life-prolonging drug; mCRPC = metastatic castration-resistant prostate cancer; OR = odds ratio;
PSA = prostate-specific antigen; REF = reference category.
* Significant at p < 0.05.
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who are AR copy neutral and those without AR-V7 [2].
Monitoring treatment efficacy in mCRPC is complex
[28]. The decision to discontinue treatment should not be
based on a single indicator for progression, but on the
association between different outcome measures (eg,
clinical, biochemical, patient-reported outcomes, and im-
aging) [12]. Consistent evaluation and reporting of clinical,
biochemical, and radiologic changes during treatment are
advised, since these can aid future research of treatment
efficacy in daily practice [12].
The first limitation of our study was the high number of
missing values, which is inherent to the retrospective design.
Missing values on baseline characteristics reflect incomplete
evaluation of patients or lack of structured reporting in daily
practice. This underlines the need for better documentationPlease cite this article in press as: Kuppen MCP, et al. Real-world O
with or Without Interposed Life-prolonging Drugs in Metastatic 
Castration-resistant Prostate Cancer Registry. Eur Urol Oncol (20at the start of a new treatment. Imputation of missing
baseline data offers a valid solution for multivariate analysis.
However, 83 patients (30%) were excluded from the imputed
analysis, which decreased the statistical power. Moreover,
because of the retrospective database, the sample size was
not based on power calculations, but on patients available
matching the study population criteria.
The second limitation was the fact that this study was
not able to capture all data on treatment decisions. Other
factors than the known patient and disease characteristics
may play a role in the decision for a particular sequence, for
example, preferences of both patients and physicians. In
sequencing ABI + P and ENZ, the possible contraindications
for prednisone could also be considered. These unknown
factors may affect outcomes. Furthermore, biomarkers
could not be evaluated in our patient population.utcomes of Sequential Androgen-receptor Targeting Therapies
Castration-resistant Prostate Cancer: Results from the Dutch
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EUO-278; No. of Pages 10Accumulating evidence points at a subgroup, identified by
noninvasive biomarkers, that benefits from ART2. These
limitations indicate the need of prospective research in a
large population to confirm the findings of this retrospective
research and putative predictive biomarkers; such research
work is currently being conducted (eg, CARD study
[ClinicalTrials.gov identifier NCT02485691] and phase 2 ran-
domised cross-over trial of ART [NCT02125357]).
5. Conclusions
In conclusion, our study suggests that PSA response rates of
ART2 are low with a short treatment duration irrespective
of sequencing both ARTs directly after each other or with
interposed TAX or Ra-223. The effect of ART2 seems to be
low, especially in patients with short time on castration,
visceral disease, and ENZ before ABI + P. Further prospective
research incorporating other outcome measures such as
overall and progression-free survival, pain, and quality of
life is necessary to aid in the optimal treatment decision
after ART1 and to possibly identify subgroups that can
benefit from ART2.
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